### Skapa referens, olika format (klipp och klistra)

**Harvard**

Lindh, M., Arnholm, B., Bjorkman, P., Hellstrand, K., Lagging, M., Nilsson, S., Wahlberg, T., Wallmark, E., Weiland, O., Wejstål, R., Westin, J., Widell, A. och Norkrans, G. (2013) *Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin*.

** BibTeX **

@article{

Lindh2013,

author={Lindh, Magnus and Arnholm, B. and Bjorkman, P. and Hellstrand, Kristoffer and Lagging, Martin and Nilsson, Staffan and Wahlberg, T. and Wallmark, E. and Weiland, O. and Wejstål, Rune and Westin, Johan and Widell, A. and Norkrans, Gunnar},

title={Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin},

journal={Journal of Viral Hepatitis},

issn={1352-0504},

volume={20},

issue={4},

pages={e82-e89},

abstract={The treatment durations for hepatitis C are guided by the analysis of hepatitis C virus (HCV) RNA in blood at certain time points. This multicentre, randomized open label trial evaluated the utility and performance of individualized treatment durations guided by viral decline rates in 103 patients with HCV genotype 1 infection. Pegylated interferon 2a and ribavirin were given as standard of care (SOC) for 24, 48 or 72 weeks or as dynamic treatment (DT) for 24–72 weeks. The DT duration was based on the time point when log HCV RNA would reach 0 log copies/mL, as estimated by the second-phase decline. The rate of sustained virologic response was 63% for SOC and 54% for DT, but this difference was not significant in multiple regression analysis taking predictive factors such as interleukin-28B genotypes, age and baseline viremia into account (P = 0.45). The mean required treatment time per cured patient was 51 weeks for DT as compared with 58 weeks for SOC (P = 0.22) when given per protocol (n = 95) and was significantly shorter (42 vs 51 weeks) among patients who achieved undetectable HCV RNA (P = 0.01). We conclude that DT was feasible and increased efficiency. The estimated time point for 0 log viral copies/mL is a new and quantitative response variable, which may be used as a complement to the qualitative variable rapid virologic response. The outcome parameter treatment weeks per cured patient could become a useful tool for comparing treatment efficiency also in the era of directly acting antivirals.},

year={2013},

keywords={HCV, interferon, kinetics, ribavirin, therapy, early viral kinetics, plus ribavirin, virus, genotype-1, peginterferon, infection, therapy },

}

** RefWorks **

RT Journal Article

SR Electronic

ID 176198

A1 Lindh, Magnus

A1 Arnholm, B.

A1 Bjorkman, P.

A1 Hellstrand, Kristoffer

A1 Lagging, Martin

A1 Nilsson, Staffan

A1 Wahlberg, T.

A1 Wallmark, E.

A1 Weiland, O.

A1 Wejstål, Rune

A1 Westin, Johan

A1 Widell, A.

A1 Norkrans, Gunnar

T1 Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin

YR 2013

JF Journal of Viral Hepatitis

SN 1352-0504

VO 20

IS 4

SP 82

OP 89

AB The treatment durations for hepatitis C are guided by the analysis of hepatitis C virus (HCV) RNA in blood at certain time points. This multicentre, randomized open label trial evaluated the utility and performance of individualized treatment durations guided by viral decline rates in 103 patients with HCV genotype 1 infection. Pegylated interferon 2a and ribavirin were given as standard of care (SOC) for 24, 48 or 72 weeks or as dynamic treatment (DT) for 24–72 weeks. The DT duration was based on the time point when log HCV RNA would reach 0 log copies/mL, as estimated by the second-phase decline. The rate of sustained virologic response was 63% for SOC and 54% for DT, but this difference was not significant in multiple regression analysis taking predictive factors such as interleukin-28B genotypes, age and baseline viremia into account (P = 0.45). The mean required treatment time per cured patient was 51 weeks for DT as compared with 58 weeks for SOC (P = 0.22) when given per protocol (n = 95) and was significantly shorter (42 vs 51 weeks) among patients who achieved undetectable HCV RNA (P = 0.01). We conclude that DT was feasible and increased efficiency. The estimated time point for 0 log viral copies/mL is a new and quantitative response variable, which may be used as a complement to the qualitative variable rapid virologic response. The outcome parameter treatment weeks per cured patient could become a useful tool for comparing treatment efficiency also in the era of directly acting antivirals.

LA eng

DO 10.1111/jvh.12014

LK http://dx.doi.org/10.1111/jvh.12014

OL 30